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High-throughput antibody generation and characterization<p>A phage displ y li rar  has been constructed ontaining over 1010 human antibodies, allowing the large-scale generation of antibodies. Over 38,000 recomb nant antibodies against 292 a tigens wer  selected, screened and sequenced, and 4,400 resultant unique clones char-act ized f rther.</p>
Abstract
We have created a high quality phage display library containing over 1010 human antibodies and
describe its use in the generation of antibodies on an unprecedented scale. We have selected,
screened and sequenced over 38,000 recombinant antibodies to 292 antigens, yielding over 7,200
unique clones. 4,400 antibodies were characterized by specificity testing and detailed sequence
analysis and the data/clones are available online. Sensitive detection was demonstrated in a bead
based flow cytometry assay. Furthermore, positive staining by immunohistochemistry on tissue
microarrays was found for 37% (143/381) of antibodies. Thus, we have demonstrated the potential
of and illuminated the issues associated with genome-wide monoclonal antibody generation.
Background
The availability of multiple genome sequences provides a val-
uable reference facilitating systematic family-wide or even
genome-wide investigation of gene function. Information on
gene structure, evolution and family relationships can be
drawn and predictions of biochemical function can be made
through sequence comparisons. Functional processes in cells,
however, are driven by proteins and a deeper understanding
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tein interactions, protein expression levels, modifications and
sites of action. Antibodies provide a valuable means of gain-
ing such information. Several initiatives to generate mono-
clonal antibodies on a genome-wide scale are under
consideration [1,2]. Large scale profiling of commercial and
newly generated polyclonal antibodies to over 700 antigens
has previously been described [3]. Panels of monoclonal anti-
bodies, however, would have advantages over polyclonal anti-
bodies by being a renewable resource of defined,
homogeneous composition. Potential cross-reactivity will be
less than in a complex polyclonal mixture. Furthermore, the
availability of multiple independent antibodies, as shown
here, allows independent verification of results.
Generation of antibodies on such a scale presents a range of
challenges, spanning the generation of antigen through gen-
eration and validation of antibodies to production, tracking
and application in a relevant biological read-out. One of the
first bottlenecks is the creation of quality recombinant pro-
tein in high throughput. This goal requires methods for
primer design, cloning, sequence confirmation, protein
expression, purification and quality control of the resulting
products. In this study, protein products derived from both
bacterial and mammalian systems were used as targets for
antibody generation. Escherichia coli provides an efficient
system for protein expression, and generation of soluble
product can be aided by addition of solubility enhancing and
affinity purification tags [4]. In addition, a protein expression
system based on transient transfection of mammalian cells
[5] was used for expression of receptor extracellular domains
[6].
Phage display is a scalable method of generating antibody
reagents, and phage-antibody libraries can provide a rich
source of antibody diversity, potentially providing hundreds
of unique antibodies per target. The antibody gene, once iso-
lated, can be conveniently shuttled into a variety of expres-
sion formats, providing a renewable resource of antibody
protein [7]. We report here the generation of an antibody
phage display library of over 1010 clones and its application to
the selection and screening of over 38,000 antibody clones.
DNA sequencing allows redundancy to be removed from the
antibody panel and permits a definitive description of the
resulting antibody gene and its product. Over 7,200 unique
recombinant antibodies to 290 targets were identified. Of
these, 4,437 were picked and their specificity determined
against a wider panel of antigens. In addition, detection sen-
sitivity was measured for 100 antibodies to 10 antigens using
a bead based flow cytometry assay, with sensitivity below
18,000 antigens/bead demonstrated for all 10 antigens. This
assay was also predictive of performance in detecting endog-
enous levels of antigen by flow cytometry. Finally, we illus-
trate their application in immunohistochemistry using tissue
microarrays to produce protein expression profiles.
Thus, we demonstrate the potential of high throughput proc-
esses for the generation and validation of recombinant pro-
teins and antibodies. We illustrate examples of information,
such as cross-reactivity, sequence, and performance data,
that may form part of a simple standardized validation proto-
col. Apart from exemplifying the potential of such large scale
approaches, the validated antibody and protein reagents gen-
erated in this study will have research and diagnostic poten-
tial and have been made available, along with the
characterization data, to the scientific community [8,9].
Results
High-throughput antibody selection
We report the construction of an antibody phage display
library of 1.1 × 1010 clones and its utilization for high through-
put antibody generation and characterization. The antibody
library was created by sequentially cloning a repertoire of
light chain variable regions (VL) followed by cloning of heavy
chain variable regions (VH). The heavy and light chain reper-
toires were created by PCR amplification from human lym-
phocytes from 43 donors, mainly collected from peripheral
blood. Human VH genes are grouped into seven families and
VL genes into six kappa and ten lambda families, based on
sequence homologies. PCR primers were designed with refer-
ence to these VH and VL germline families [10]. The full set of
primers along with detailed protocols for their use are listed
in Additional data file 1.
In a first step, the VL repertoire was cloned into the NheI/
NotI sites of pSANG4 (Figure 1). Subsequently, plasmid DNA
was prepared from this library before cloning the VH reper-
toire into the NcoI/XhoI sites. The final format of the anti-
body is a single chain Fv (scFv) with VH and VL fragments
joined by a flexible linker peptide (Gly4 Ser Gly4 Ser Gly3 Ala
Ser).
The library was generated using B lymphocytes from 42
human peripheral blood donations and 1 tonsil. Diversity was
maintained at a maximum by a variety of strategies. All dona-
tions were maintained separately and combined to 11 pools at
the mRNA stage. V region primers (14 heavy chain, 13 kappa
light chain and 15 lambda light chains) were kept separate
during primary PCR for each of the 11 mRNA pools, that is,
462 separate primary PCR reactions were performed. Each of
the kappa light chain families and three pools of the lambda
chain families were transformed separately and only pooled
into two master sets (kappa and lambda) once DNA was iso-
lated from each library stock to prepare vector for heavy chain
cloning. Transformation of each of the 7 heavy chain families
into both the kappa and lambda light chain libraries was done
separately creating a total of 14 pools of scFv libraries, supple-
mented with 2 additional sub-libraries representing VH3/
Vkappa1 and VH/kappa3 combinations. Finally, phage were
prepared individually from each of the 16 different aliquotsGenome Biology 2007, 8:R254
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Schematic representation of the process for the high throughput generation and screening of recombinant antibodies.
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sub-aliquot.
Phage particles were rescued using a trypsin sensitive helper
virus [11]. Thus, phage particles incorporating the minor coat
protein encoded solely from the helper phage are susceptible
to trypsin cleavage and will not be infective. In contrast, those
displaying an antibody-gene 3 fusion will retain infectivity
after trypsin treatment. This reduces background from 'non-
participating' phage particles that have been generated with-
out utilizing an antibody-gene 3 product from the library.
This increased the efficiency of binder isolation such that we
routinely required only two rounds of selection. High
throughput selection was further facilitated using a liquid cul-
ture amplification/rescue method, eliminating the need for
plating out and scraping of bacterial culture plates.
Antibodies were selected to 404 antigen targets (representing
280 genes) that were primarily produced in E. coli [4] or in
mammalian cells [6], with a proportion sourced commer-
cially. The majority of genes (214/280) were cell surface
receptors, with 30% of the immunoglobulin superfamily rep-
resented (139 genes). Receptors were chosen as they com-
prise a major class of drug targets that provide information on
the communication potential of cells, and act as identifiers of
different cell types, which can be used in their purification.
Most of the genes were murine in origin (81%), with the
remainder being human (18%) and rat (1%). A full gene list is
provided at the 'Antibody Atlas db' [8] and in Additional data
file 2.
Following selection, resultant antibody populations were sub-
cloned into an expression vector (pSANG14-3F), which fuses
the antibody scFv to a tri-FLAG tag sequence and the dimeric
enzyme bacterial alkaline phosphatase. This provides a con-
venient enzymatic tag to detect binding as well as driving
dimerization, thereby increasing avidity of binding [7]. From
each selection, 94 clones were screened and sequenced, and a
sub-set of up to 22 unique clones identified for further specif-
icity and sequence characterization. The process is outlined in
Figure 1.
Primary screening and sequencing of selected 
antibodies
The primary screening assay to identify binders was initially
performed with bacterial lysates in a 96-well format using
direct detection of alkaline phosphatase fused to the antibody
fragment. This convenient assay requires no secondary anti-
body and involves a single cycle of binding and washing of the
antibody-alkaline phosphatase fusion, followed by addition of
enzymatic substrate. In subsequent work, the assays were
performed in a 384-well format using europium labeled sec-
ondary reagents, to more closely reflect the system we used
for secondary screening (see below).
To identify unique binders, all primary clones were
sequenced using a single primer that annealed upstream of
the 5' end of the VH gene. In total, 38,164 clones were
screened and sequenced. Of these, 9,384 were positive in pri-
mary screening ELISA. Sequence analysis of all of these iden-
tified 7,236 unique clones. With 292 antigens passing
selection, this represents a success rate of 72% with an aver-
age of 25 clones for each positive antigen.
Figure 2a shows the number of unique scFv binders gener-
ated for each target, demonstrating the diversity achieved
from the library. This figure compares the success rates of
protein generated in both bacterial and mammalian expres-
sion systems. It is clear that the performance of targets
derived from mammalian expression systems were superior
in terms of generating target specific, sequence unique scFvs.
For bacterially expressed antigens, 54% of the targets gave
rise to one or more unique binders after the primary screen-
ing ELISA stage, with 19% giving rise to 22 or more unique
clones. For mammalian expressed antigens, 82% of the tar-
gets gave rise to one or more unique binders after the primary
screening ELISA, with 52% giving rise to 22 or more unique
clones. The diversity of antibodies generated from the library
across a wide range of antigens clearly illustrates the quality
of the library and methods used. Furthermore, it suggests
that more screening would generate a greater diversity of
antibodies. Generation of hundreds of antibodies to a single
antigen using a similar antibody phage display library has
previously been described [12].
High throughput generation and characterization of recombinant antibodiesFi ure 2 (see following page)
High throughput generation and characterization of recombinant antibodies. (a) For each target antigen, 94 clones were screened in ELISA and sequenced 
to identify unique clones. The plot shows the number of antigens selected (x-axis) versus the number of unique positive antibodies generated (y-axis) for 
each antigen. Separate plots are presented for antigens produced in either bacterial or mammalian expression systems, illustrating the improved success 
rate for mammalian antigens. (b) Example specificity data for antibodies selected against Slam f9 (produced in the HEK293 mammalian expression system). 
All antibodies are screened against target antigen, the relevant fusion partner that was used in selection, keyhole limpet hemocyanin (KLH), thyroglobulin, 
myoglobin, cytochrome c, human IgG, laminin, fibronectin, α-glycerol phosphate dehydrogenase, and total protein lysates from zebra fish (D. rerio) and 
yeast (S. pombe). Results are shown for 22 different antibodies as well as our routine anti-desmin control (des-D7) and a no antibody control. Detection 
was via time resolved fluorescence and values are shown on a logarithmic scale. (c) Global summary of secondary ELISA data for all antibodies in 
secondary screening. Signal generated on specific antigen is shown for all 4,437 samples (solid block). Signal achieved on one of the ten irrelevant antigens 
(cytochrome c) is also shown.Genome Biology 2007, 8:R254
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were clustered according to the heavy chain complementarity
determining regions (CDRs) with a particular focus on CDR3,
which is most variable. Clones were also ranked according to
signal-to-noise ratio in primary screening ELISA with prior-
ity given to clones with the highest signal-to-noise ratio and
most divergent HCDR3 amino acid sequences. Up to 22 scFv
clones were chosen for each target, yielding 4,437 antibodies
to 286 antigens for specificity testing and high quality
sequencing.
To give a definitive description of each antibody, all 4,437
clones undergoing secondary screening were sequenced in
depth with 6 primers covering the VH and VL gene segments
in both forward and reverse orientation. A consensus
sequence was generated and the most closely related VH and
VL germ line sequences were identified (Figure 3). This was
done by comparing the VH and VL segment of each clone
against a database of human antibody germline genes. The
database uses 51 VH germline genes (across 7 sub-families,
VH1-VH7), 40 germline V kappa genes (across the 6 sub-fam-
ilies Vkappa 1-Vkappa 6) and 31 germline V lambda genes
(across the 10 V lambda families) [10]. Analysis shows that all
VH, Vkappa and V lambda sub-families were represented in
the selected population and most individual germline genes
were identified as the closest hit in at least one selected clone.
Thus, the full repertoire of antibody germline genes is being
accessed during selection of the library. Figure 3 shows the
frequency of different combinations of the VH, Vkappa and V
lambda sub-families in the selected repertoire. Although the
relative contribution of each germline family was normalized
in the construction of the library, the results show a dispro-
portionate occurrence of certain germline families (VH1,
VH3, Vkappa 1, Vlambda 6). Consistent with previous work,
this may reflect a greater degree of antibody diversity within
these families in the initial library or may reflect emergence of
clones during selection or screening as a result of improved
expression from these families [13]. As well as assigning the
closest germline gene for each clone, a detailed analysis was
conducted to identify position and sequence of the framework
and CDRs and this information is available at the Antibody
Atlas db [8].
Secondary specificity screening
The selected clones were tested in a secondary screening
assay in order to confirm the results of the primary screening
ELISA, and to identify antibody clones that were cross-reac-
tive with a panel of irrelevant proteins. Each antibody clone
was tested against the target antigen, the fusion partner used,
eight irrelevant purified proteins and total protein lysates
from zebrafish and yeast, representing more complex non-
mammalian protein mixes. All secondary specificity screens
took advantage of the sensitivity and dynamic range of time
resolved fluorescence using europium labeled secondary anti-
bodies. Figure 2b shows a representative cross-reactivity pro-
file on all 12 antigens, for 22 antibodies generated to a single
antigen. In a global view of the data, Figure 2c summarizes
the range of ELISA signals achieved on secondary screening
for all 4,437 clones on their specific antigen compared with
the signal generated from one of the irrelevant antigens (cyto-
chrome c). This illustrates that the signals achieved span
three orders of magnitude. The signal level achieved is
dependant on multiple factors, including efficiency of antigen
coating, expression level of each antibody and the affinity of
that antibody for antigen. Using 1,000 fluorescence units as a
threshold, 76.6% of clones undergoing secondary screening
were considered positive. Within this group, 80% of clones
were specific for target antigen (defined as absence of signal
above 1,000 units on all other antigens). Twelve percent of
cross-reactivity assay failures at this stage were from antibod-
ies that recognized the antigen fusion partners. Thus,
although deselection with the fusion partner reduced the pro-
portion of fusion binders generated, it did not completely pre-
vent such antibodies arising.
The above analysis shows that 23% of clones deemed positive
on primary screening were scored as negative on secondary
screening. For many this was due to the increased stringency
in the secondary screen since many of these failures were also
the poorest performers in the primary screen. For five anti-
gens, all antibody clones were negative on secondary screen-
ing, and in these cases the antigen was assumed to have
precipitated over time in storage. This was substantiated in
one case where the clones were positive on the same antigen
in an alternative antigen construct (not shown).
Mirroring the primary screening results, antibodies to mam-
malian-produced antigens had a higher success rate in sec-
ondary screening, where 64% of antibodies generated were
confirmed as antigen specific and, of those, 69% were scFv
with high secondary ELISA scores (defined as 10-fold above
the cut off, that is, 10,000 Europium units). In contrast, 57%
of scFv generated to bacterially produced antigens were con-
firmed as antigen specific on secondary screening and, of
those, 54% had high secondary ELISA scores. Analyzing the
data by antigen target showed that 88% of all targets had at
least one antigen-specific binder in the cross-reactivity assay,
and 89% of these had at least one binder with high secondary
ELISA score. In conclusion, secondary screening has con-
firmed the results of the initial high throughput screen for the
majority of clones and has demonstrated high specificity for
the target antigen in 80% of cases.
Assessing performance of antibodies
Although affinity is a useful definitive measurement in
describing the properties of an antibody, measurement of
absolute affinities for thousands of clones is impractical. A
relative ranking of clones is possible using inhibition ELISA
[14] or, more simply, with an end-point ELISA, provided the
antibody concentration is normalized and the signal is within
the dynamic range of the detection system. The ultimate
measure of antibody utility, however, relates to performanceGenome Biology 2007, 8:R254
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Frequency of VH and V kappa/V lambda germline gene combinations selected from the library. High quality sequence of all 4,437 clones undergoing 
secondary screening was generated by sequencing with six primers covering the VH and VL gene segments in both forward and reverse orientations. A 
consensus sequence was generated and the most closely related antibody germ line genes were identified. (a) Frequency of different combinations of VH 
and V kappa/V lambda germ-line genes occurring in the selected antibodies, represented both numerically and by color coding. (b) Frequency of different 
combinations of VH and V kappa/V lambda germline genes among the selected antibodies.
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When using biological samples, however, many factors apart
from affinity affect the outcome, for example, level of antigen
expression, modification of targets, effect of fixation, and so
on. To assess the performance of a panel of antibodies in flow
cytometry, independently of these factors, we have employed
an assay using beads with defined antigen capture capacity
ranging from 0 to >600,000 copies per bead. The read out
from this assay gives an indication of the potential level of
sensitivity a given antibody may have in cell based flow
cytometry. Figure 4a shows staining of Jagged-1 coated
beads, illustrating detection capability below 10,000 copies
per bead for 4/9 antibodies. Normalized ELISA provides an
alternative means of ranking antibodies and Figure 4c dem-
onstrates a correlation between signal achieved in normalized
ELISA and performance in the bead based assay.
Using Jagged-1 as an example, we show that performance in
the bead assay in turn correlates with ability to detect endog-
enous levels of antigen. Jagged-1, which is expressed on
embryonic stem cells [15] is a ligand for Notch receptors. The
Notch signaling system is an ancient and widely used pathway
in metazoan development and evolution, where it links the
fate of one cell to its neighbors. Notch signaling involves a bi-
molecular interaction between receptor and ligand on oppos-
ing cells. Mammalian notch signaling involves a choice of four
notch receptors (Notch 1-4) and five ligands (Jagged 1,2, delta
1,3,4). Flow cytometry analysis of ES cells stained with three
different anti-Jagged-1 antibodies is shown in Figure 4b. This
shows that signal intensity varies with different antibodies
and this, in turn, corresponds to the performance ranking
found in the bead based assay.
The bead assay was applied to 90 other antibodies represent-
ing 9 different target genes. In this experiment beads were
coated with antigen at a range of densities (18,000, 57,000,
459,000 antigens/bead). To help summarize and present the
results for all 90 antibodies, the median fluorescent intensity
for the bead coated with 459,000 target molecules was calcu-
lated. The signal relative to that of uncoated bead is plotted in
Figure 5 and shows a wide range of signals up to 4,000-fold
over background (values and antibody names are given in
Additional data file 3). Detection of beads coated with 18,000
copies per bead was achieved with at least one antibody for all
9 genes tested. The sensitivity limit is illustrated in Figure 5
by using different data point symbols to indicate the lowest
antigen density detected for each antibody. In summary, sen-
sitive detection in bead based flow cytometry has been dem-
onstrated for a large panel of the antibodies and detection of
endogenous levels in cultured cells exemplified by Jagged-1 in
embryonic stem cells.
Expression profiling using tissue microarrays
We used 381 antibodies that had passed secondary screening
to stain acetone fixed frozen tissue microarrays. From this
survey, positive staining was observed for 143 (37%) antibod-
ies representing 46/56 antigens tested. Figure 6a-c illustrates
an example of an anti-CD5 antibody giving expected staining
of scattered human lymphoid cells in lymph node, skin and
Peyers patches [16]. We also illustrate immunohistochemical
staining with some of the antibodies discussed in previous
sections. For example, Figure 4d illustrates detection of
endogenous levels of Jagged-1 in the developing kidney of a
14.5 day embryo. This result was confirmed by in situ hybrid-
ization as shown in Figure 4e. In addition, the three best per-
forming antibodies against nerve growth factor receptor
(Ngfr) illustrated in Figure 5 also detected endogenous levels
of Ngfr in immunohistochemistry. With these antibodies,
expected peripheral nerve staining [17] was present in several
adult cores, including large ducts in salivary gland and
oesophagus (Figure 6d). Occasional clustered staining was
seen in sagittal brain and was also present in a 14.5 day
murine embryo where the edge of the central nervous system
and spinal cord, choroid, dorsal root ganglia and large nerve
tracks were stained strongly (Figure 6e).
Phage display provides the opportunity to generate multiple
independent antibodies to provide confirmation of generated
expression profiles. Details of overlapping staining profiles
with multiple antibodies are given (Additional data file 4). In
summary, we demonstrate that it is possible to generate anti-
bodies in high throughput for use in protein expression pro-
Assessing performance of a panel of anti-Jagged-1 antibodiesFigure 4 (s e previous page)
Assessing performance of a panel of anti-Jagged-1 antibodies. (a) Flow cytometry calibration beads with varying number of anti-human Fc antibodies were 
coated with Jagged-1-Fc fusion to yield antigen display levels of 29,000, 83,000, 204,000 and 619,000 Jagged-1 molecules/bead. These were labeled with a 
panel of different recombinant antibodies raised against Jagged-1 and binding was detected with labeled anti-FLAG antibodies. The resulting histograms are 
shown, giving different levels of sensitivity. In Jag1_D5 for example, five peaks are visible corresponding to uncoated beads and each of the four antigen 
coated beads. In the case of Jag1_C5, where there is lower sensitivity, only the two beads with highest density are resolved while the others merge with 
that of the uncoated bead. Where all four beads are clearly resolved, we have calculated the theoretical limit of detection of receptors per bead (Rec. #). 
(b) 46C mouse embryonic stem cells were stained with the panel of Jagged-1 antibodies and analyzed by flow cytometry. Staining for three antibodies 
(Jag1_D5, Jag1_D7 and Jag1_A1.2) is shown. The sensitivity of each corresponds to that seen in the bead assay above. (c) A plot of normalized ELISA 
scores with performance in the bead-based flow cytometry performance assay for nine Jagged-1 specific antibodies. ELISA was carried out using 1 μg/ml of 
purified antibody. The mean time resolved fluorescence score (expressed as Eu counts) was plotted against median fluorescent intensity determined for an 
antigen density of 618,888 antigens/bead. The line represents a linear regression analysis of the data (R2 value = 0.8323). (d) Immunohistochemical 
(Jag1_A6 scFv antibody) and (e) in situ hybridization staining of Jagged-1 in developing kidney of E14.5 mouse embryo, demonstrating localization of staining 
(dark purple) in developing renal tubules.Genome Biology 2007, 8:R254
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consistent with that achieved using hybridoma derived mon-
oclonal antibodies and polyclonal antibodies [3,18,19].
Discussion
We describe the creation of an antibody phage display library
of over 1010 clones and its application to high throughput anti-
body generation and characterization. Many factors affect
success rate throughout the individual steps of the process
described here. For example, success rate of protein expres-
sion is variable and we have previously described the effect of
sequence features and choice of fusion partner in E. coli
expression [4]. In E. coli, receptor extracellular domains were
particularly badly expressed, resulting in insoluble inclusion
body formation (not shown). This may reflect a requirement
for receptors to be trafficked through a eukaryotic secretion
system, to ensure correct disulphide bond formation, native
protein folding, good secreted protein expression yields and
protein stability during purification and storage. In this study
we have therefore utilized both bacterial expression and a
transient expression system based in mammalian cells [6].
We used the mammalian expression system for receptor
extracellular domains, which were the major class of proteins
expressed in this system.
Table 1a summarizes the success rate achieved for this class of
protein. Approximately 70% of gene constructs gave rise to a
soluble product in culture supernatant, as judged by western
blot using an anti-His tag antibody (not shown). For 62% of
the positive constructs, 50 μg of purified protein were puri-
fied from a 50 ml culture, providing sufficient material for
antibody generation/screening. The success rate was
improved further in some cases by adjusting the boundaries
of the expressed domain and by using larger culture volumes
(unpublished).
The selection success rate was dependent on the antigen
source, with mammalian produced antigens being superior to
bacterially produced antigens (Figure 2, Table 1b). In mam-
malian systems, misfolded proteins are degraded [20], and
this additional quality control may have led to improved
selection results. In contrast, most of the bacterially produced
proteins were fused to tags such as maltose binding protein
(MBP), which enhanced production of soluble product [4].
Although this has improved the yield of soluble product, it is
possible that there is a greater proportion of misfolded pro-
tein in the bacterially produced antigen preparations depend-
ing on the protein target being expressed [21-23], giving
higher backgrounds and compromising selections. For exam-
ple, expression of the HPV oncoprotein E6 in E. coli as an
Detection sensitivity in a bead-based performance assay for a panel of antigensFigure 5
Detection sensitivity in a bead-based performance assay for a panel of antigens. The sensitivity limits of 90 antibodies to 9 different antigens were tested 
using a mix of antigen coated beads of different antigen densities. To summarize these data, the relative median fluorescent intensity on the bead 
comprising 459,000 antigen copies per bead was calculated (actual values and clone IDs given in Additional data file 2) and the ratio relative to uncoated 
beads plotted. To further illustrate sensitivity achieved, the identity of the lowest density bead that could be detected is indicated by the data label 
according to the following guide: 459,000 antigen copies per bead only (diamonds), down to 57,000 antigen copies per bead (square), and down to 18,000 
antigen copies per bead (triangles). The antigens were: 1, Efna2; 2, Efna4; 3, Plaur; 4, Alcam; 5, Il13ra1; 6, Sigrr; 7, Ngfr; 8, Cd22; and 9, Vcam1.
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major fraction was misfolded aggregate with a minor fraction
containing properly folded protein with full biological activity
[24].
Where antibodies are raised by selection on native like pro-
tein (for example, by phage panning on extracellular domains
generated by mammalian expression), it might be expected
that many of the antibodies produced will recognize the
High throughput immunohistochemistry on tissue microarraysFi ure 6
High throughput immunohistochemistry on tissue microarrays. Example data demonstrating cell surface staining of (a-c) CD5 (antibody ant165_155_E04) 
on lymphocytes in human lymphoid tissue, (d-e) nerve growth factor receptor (antibody ant54_71_C07) in nerve bundles attached to the murine 
esophagus and in developing nerve tracts in E14.5 embryo and (f-h) nuclear staining of the transcription factor ELF1 (antibody ant46_62_F12) in cerebrum, 
liver and uterus. Tissues are: (a) lymph node; (b) skin; (c) Payer's patch in small intestine; (d) murine nerve bundles in esophagus; (e) nerve tracts in 14.5 
day embryo with myoblast sheet above; (f) cerebrum; (g) liver; and (h) uterus.
(d) (e)
(a) (b) (c)
(f) (g) (h)Genome Biology 2007, 8:R254
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bodies of both native and denatured forms will then be
dependant on whether the target epitope is available after
denaturation, for example, within fixed tissues. This is in con-
trast to other approaches where denatured antigens are used
to raise antibodies, for example, by immunization [3,18,19].
Here, recognition of native antigen by antibodies raised on
denatured antigen will depend on whether the linear epitope
is found in native conditions. Thus, antibodies raised by dif-
ferent approaches may have different utility in recognizing
native protein and different sensitivities to fixation/denatur-
ation.
In general terms, we observe a success rate of 37% for gener-
ating a positive profile (Table 1d; detailed in Additional data
file 3), which is broadly similar to that described previously
[3,18,19]. It is difficult, however, to compare immunohisto-
chemistry results in a more specific way across projects since
different organisms, genes and antibody generation/fixation
regimes are used. In addition, specificity of antibody staining
is an important consideration and different groups verify
staining patterns to different extents. For example, false pos-
itive binding to unrelated antigens can occur, not just with
polyclonal antibodies, but also with monoclonal antibodies,
as exemplified by previous studies with antibodies on protein
microarrays [25-27]. In a similar way, exposing hybridoma
derived monoclonal antibodies to the majority of tissue in the
body has been shown to result in false positive staining [18].
Systematic verification of staining patterns from expression
databases or literature can provide supporting evidence (for
example, widespread nuclear expression of ELF1 (Figure 6g-
i)). In situ hybridization can also provide supporting evidence
that a given profile is correct (as exemplified for Jagged-1 in
Figure 4d,e). Finally, the availability of multiple antibodies to
the same target can increase confidence in the veracity of a
given profile by independently generating similar or identical
profiles [18]. Among the positive antibodies profiled here, 58
antibodies (15 genes) represented cases where more than one
antibody gave the same or overlapping profiles (examples in
Figure 6 and summarized in Additional data file 3).
Here, we show the feasibility of antibody generation in a high
throughput manner. The bottlenecks in this process was not
antibody generation but the cloning, verification and genera-
Table 1
Success rates in protein expression, antibody isolation and immunohistochemistry
Step Number Percentage
(a) Mammalian expression of receptor extra-cellular domains
Sequenced confirmed clones 157 100%
Detected in supernatant by western blot 108 69%
50 μg purified product generated from 50 ml culture 67 62% (43% cumulative)
(b) Success rate of antigens in generation of antibodies
Mammalian antigens for selection 205 100%
Antigens generating antibody 181 88%
Bacterial antigens for selection 192 100%
Antigens generating antibody 103 54%
Total antigens for selection 404 100%
Antigens generating antibody 292 72%
(c) Success rate for primary antibody screening
Number of antibodies screened 38,164 100%
Number positive on primary screen 9,384 24.6%
Unique clones generated 7,236 77.1% (19% cumulative)
(d) Success rate for secondary antibody screening
Clones undergoing secondary specificity screening 4,437 100%
Positive in secondary screening 3,400 76.6%
Specificity demonstrated 2,725 80.1% (61% cumulative)
(e) Success rate in immunohistochemistry
Stained on tissue microarrays 381 100%
Positive staining observed 143 37%Genome Biology 2007, 8:R254
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antibodies in downstream applications, for example, in
immunohistochemistry. The library and selection process
employed was particularly effective, resulting in 7,236 unique
antibodies from screening and sequencing 38,164 clones
(Table 1c). From 292 successful selections, an average of 25
unique binding antibodies was generated for every 94 clones
screened. The success was due to steps taken during library
construction to maintain diversity to a maximum and also
due to optimization of the selection and screening process
(discussed previously in Results). Having developed the
library and established the system for carrying out this
process, 48-96 antigens can be selected and undergo primary
screening and sequencing by 2 people over a 6 week period.
In this study we have sequenced and screened 38,000 anti-
bodies and describe different degrees of characterization for a
proportion of these, ranging from specificity ELISA through
to detection of endogenous levels of antigens using arrays of
adult tissue. A standardized system of validation of antibodies
across multiple labs would add to the value of high through-
put antibody generation initiatives and the use of antibodies
in general. Antibody characterization is complex, however,
since the utility of antibodies is application dependent and is
subject to many factors, including endogenous levels of anti-
gen expression, availability of epitopes and their sensitivity to
fixation or denaturation, antibody affinity/specificities and
the sensitivity of detection system used. The affinity of an
antibody for a given antigen is a property that can be meas-
ured in absolute terms and is related to performance, pro-
vided the test antigen accurately represents the target antigen
in a biological sample. Affinity determination using surface
plasmon resonance provides accurate affinity values but is
laborious and requires specialist equipment that is not
universally available. Inhibition ELISA can, within limita-
tions, also provide affinity values [14]. In this study we have
utilized a simple, sensitive end-point ELISA assay with wide
dynamic range to measure binding and permit performance
ranking of the clones (following normalization of antibody
concentration). We have also introduced a surrogate per-
formance assay for flow cytometry, replacing cells with beads
with different antigen coating densities, allowing a
measurement of sensitivity in terms of target density per
bead. In a similar way, a simple surrogate could be envisioned
to rank the potential of clones as western blot reagents by
measuring detection limits of denatured antigen on support
matrices such as PVDF. While such assays do not guarantee
success with biological samples, they can facilitate ranking of
clones for subsequent investigations.
Antibody specificity is another important property that
relates to the relative affinity for other 'irrelevant' epitopes.
Cross-reactivity can arise through conserved interactions
with related antigens or by 'polyspecificity' involving different
modalities of binding to unrelated antigens [28,29]. It is dif-
ficult to be definitive about measuring cross-reactivity since it
depends on what antigens are presented in any application.
Immunohistochemistry on microarrays of fixed tissues to
determine global protein expression pattern represents a par-
ticularly challenging application with a high proportion of the
proteome being presented at varying levels. Nonetheless, in
this study we demonstrate specific detection of non-abundant
proteins and provide supporting data from independent anti-
bodies, in situ hybridization or alternative data sources to
confirm the resultant staining profiles for a proportion of
these (Additional data file 3).
To identify obviously cross-reactive clones in a simple 'first
pass' assay, we have used a panel of 11 irrelevant antigens,
including non-mammalian lysates. Protein microarrays or
multiplex bead assays would be more informative in provid-
ing a wider range of proteins and these may become more
widely available in the future. Standardized western blotting
of irrelevant tissue lysates (such as yeast/zebrafish lysates
used here) may provide an alternative source of 'arrayed'
irrelevant proteins using a technique currently available in
many labs that could identify binders with relatively low
specificity.
Conclusion
Historically, antibody validation has been ad hoc, making it
difficult to compare antibodies from different sources, result-
ing in much wasted effort and cost. Here we demonstrate the
high throughput generation and validation of recombinant
antibodies on an unprecedented scale. Large scale efforts to
generate and validate antibodies will not only provide a
wealth of reagents for research and diagnostics, but could also
drive the introduction of a more consistent quality control
framework to facilitate comparisons of binders from different
sources for use in different applications, whatever the source.
Materials and methods
Antigen cloning and expression
Antigens were obtained either from commercial sources, or
were expressed from E. coli or transient mammalian expres-
sion systems using systems we have described previously
[30]. For primer design, mRNA sequence was downloaded
from the Ensembl entry [31] with coding and 5' and 3'
untranslated region (UTR) annotation. Pfam domains [30]
were annotated onto the nucleic acid sequence and primers
designed to amplify either the full-length open reading frame
or specific Pfam domains. Inserts were amplified from cDNA
using nested PCR, as described previously [4], GATEWAY
cloned into expression vectors [32] and DNA sequence
confirmed. All steps in antigen production, including PCR
amplification, sequence confirmation, expression and purifi-
cation, were electronically tracked using a custom designed
laboratory information management system (unpublished).
In the case of automated primer design of the immunoglobu-
lin superfamily (IgSF), targets were identified from a searchGenome Biology 2007, 8:R254
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ENSMUSP (protein) entries that contained annotated IgSF
Pfam domains and signal peptides. The transcript sequence
with annotated protein features, including coding sequence
signal peptides, transmembrane (TM) regions and Pfam
domain boundaries, were batch downloaded and used as a
template for automated primer design. Outer primers were
designed to the UTRs to amplify the full-length open reading
frame using Primer3 [33]. Three design strategies were
employed for the inner primers: EC+SIGP-euk, coordinates 1
to minus 5 amino acids upstream of the TM, minus a stop
codon for HEK293E expression with carboxy-terminal tags;
EC-SIGP-pro, coordinates plus 1 amino acid downstream of
the SIGP to minus 5 amino acids upstream of the TM plus a
stop codon for E. coli expression with amino-terminal tags;
and IC-pro, coordinates plus 5 amino acids downstream of
the TM to the end of the coding sequence plus a stop codon for
E. coli expression with amino-terminal tags.
Our E. coli protein expression system was described previ-
ously [4] and utilizes the T7 RNA polymerase promoter driv-
ing cytoplasmic expression in BL21-DE3 cells (Novagen,
Nottingham, UK). This line has an inducible RNA polymerase
gene under the control of the lac promoter. Expression was
performed using either shake flasks or 24-well blocks with the
Studier auto-induction protocols [34]. Most proteins were
expressed with an amino-terminal decahistidine (His10) tag
for affinity purification and either a thioredoxin (Trx) or MBP
solubility enhancing fusion. In common with many low
molecular weight eukaryotic proteins [4], the Rab proteins
did not require a solubility enhancing fusion for high level sol-
uble expression. Expression in mammalian cells was by tran-
sient transfection of HEK293E suspension cells [6] with
expression vectors designed to add a carboxy-terminal His10
tag or His10-rat Cd4 (domains 3 and 4) fusion [35]. Most
receptor ectodomains were expressed in HEK293E cells at a
50 ml culture volume, but low expressing clones were scaled
up to a 200 ml culture volume. Proteins were affinity purified
using a FPLC system or Qiagen8000 robot. All proteins were
subject to a quality control procedure before handover for
antibody selection, which required a minimum of 50 μg and
greater than 80% purity of full-length target protein. Proteins
were stored in a buffer containing 50% or 10% glycerol for -
20°C or -80°C storage, respectively
Construction of pSANG4 display vector
A modified version of the phage display vector pHEN1 [36]
was constructed by inserting a novel/cloning linker region.
This was created by annealing primers NcNotlinkS and
NcNotlinkA, extending with DNA polymerase and cutting
with NcoI/NotI before cloning into the NcoI/NotI site of
pHEN1 to give pSANG3. This allows sequential cloning of
antibody light chains via NheI/NotI and heavy chains via
NcoI/XhoI. The pelB signal sequence in pSANG3 was
replaced with the signal sequence from M13 gene 3 to create
the vector pSANG4. This leader is potentially more useful for
ligation independent cloning. (Ligation independent cloning
allows direction cloning without restriction enzymes or ligase
enzymes, by using the 5'-3' exonuclease activity of DNA
polymerase to create single stranded overhangs for anneal-
ing. The presence of a single nucleotide causes the exonucle-
ase activity to arrest where that nucleotide becomes
incorporated and so long overhangs can be engineered [37].)
The M13 leader and 5' UTR were created by annealing oligo-
nucleotides G3HindNdeS and G3NcoA (see Additional data
file 4), extending with DNA polymerase (Novagen), digesting
and cloning into the HindIII and NcoI sites of pSANG3.
G3HindNdeS is based on the sequence of M13 but adds a stop
codon to stop elongation initiated at the lacZ start codon,
which is upstream in the vector. The primers also introduce a
new NdeI restriction site at the start of the leader sequence
and introduce a silent mutation in the tenth codon of the
leader with a view to increasing the potential overhang in liga-
tion independent cloning. Constructs were confirmed by
sequencing with primers LMB3 and fdtseq1. The resultant
vector, pSANG4, is represented in Figure 1 and more fully
described in Additional data file 4.
Construction of display library
An antibody phage display library was created by sequentially
cloning a repertoire of light chain variable regions (VL) fol-
lowed by cloning of heavy chain variable regions (VH) in
pSANG4. The VH and VL pools were cloned through primer
encoded NcoI/XhoI and NheI/NotI sites, respectively. The
VH and VL domains were initially cloned into an intermedi-
ate, out of frame cloning vector, pSANG2. The final format of
the antibody is a scFv with VH and VL fragments joined by a
flexible linker peptide (Gly4 Ser Gly4 Ser Gly3 Ala Ser).
A more detailed description of the library construction is pro-
vided in Additional data file 4. In brief, antibody heavy and
light chain variable region repertoires were created by PCR
amplification from human lymphocytes. Fourteen heavy and
28 light chain primer pairs were used and maintained sepa-
rately in 462 separate primary PCRs with cDNA originating
from 43 lymphocyte donors. Light chains were cloned as
NheI/NotI fragments. To maintain diversity, the VL reper-
toire was cloned as 9 separate sub-libraries with an average of
107 clones per library (6 kappa families and 3 pools of lambda
families). Plasmid DNA was prepared from these and pooled
into two separate kappa or lambda chain sets. The VH reper-
toire was sub-cloned via NcoI/XhoI sites to these two light
chain libraries. Fourteen different sub-libraries were pre-
pared, consisting of each of the seven heavy chain families
(VH1-VH7) combined with either kappa or lambda light
chains. It has been suggested [13] that particular
combinations of VH and VL families express better and so
two additional sub-libraries of VH3/κ3 and VH3/κ1 were
generated, giving a combined total of 1.1 × 1010 inserts in the
'McCafferty' phage display library.Genome Biology 2007, 8:R254
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Rescue of phage particles from the library was carried out
essentially as described [38] but using trypsin-cleavable
helper phage [11,39], which increased the efficiency of binder
isolation such that only two rounds of selection were
required. Selection was as described previously [38] with the
following modifications (described in more detail in Addi-
tional data file 4). Following the rescue of the individual
library aliquots, the antibody-phage particles were purified
by sequential polyethylene glycol precipitation (Sigma, Poole,
UK) and cesium chloride gradient centrifugation and the
quality assessed by confirming the presence of full length
antibody-gene 3 fusion by western blotting using anti-gene 3
antibody (New England Biolabs, Hitchin, UK; data not
shown). Each aliquot was titrated and pooled according to the
size of the aliquot to normalize the contribution of each clone.
Final concentration was 1013 colony forming units/ml and 50
μl was used per selection. For the selections, each antigen was
coated at 10 μg/ml onto a single well of a 96-well microtiter
plate. We routinely performed a deselection process before
commencing the first round of selection for recombinant pro-
tein targets with common fusion partners, for example,
human IgG1 Fc, rat CD4 (domains 3 and 4), MBP, and Trx.
This procedure helped to deplete binders to fusion partners.
Two rounds of selections were performed using the 'McCaf-
ferty' scFv antibody-phage library. Following binding of the
library to immobilized antigen, phage were eluted in 100 μl of
freshly prepared 125 μg/ml TPCK-trypsin (Sigma) in 50 mM
Tris pH 8, 1 mM CaCl2 at room temperature for 15 minutes. A
mid-log culture of E. coli TG1 cells (200 μl) was added to each
well containing the eluted phage and shaken slowly (150 rpm)
at 37°C for 1 hour. At this stage aliquots can be taken to titer
the output. Bacteria were pelleted at 3,000 × g for 10 minutes,
resuspended in 500 μl of 2 × TY medium with ampicillin and
2% glucose (2 × TY amp/glu) and grown overnight at 30°C.
The next day, 1 ml cultures of 2 × TY amp/glu in a deep well
plate were inoculated with 20 μl of the overnight culture and
incubated at 37°C for 1 hour at 600 rpm. Helper phage were
added to a MOI of 10 and incubated with gentle shaking at 150
rpm at 37°C for 1 hour. Bacteria were pelleted at 3,000 × g for
10 minutes, resuspended in 500 μl 2 × TY medium with amp-
icillin and kanamycin and incubated overnight at 30°C with
shaking at 600 rpm. The selected outputs were then evalu-
ated for specific antigen binding using phage ELISA [40].
Individual, selected scFv colonies were rescued as scFv-phage
particles in 96-well microtitre wells and transferred to spe-
cific antigen (5 μg/ml) coated wells. Anti-M13-horseradish
peroxidase conjugate (GE Healthcare, Little Chalfont, UK)
and 3,3',5,5'-tetramethyl benzidine substrate (Sigma) were
used to detect bound phage.
Sub-cloning selected populations
Prior to screening of individual clones, the selected popula-
tions were sub-cloned into an expression vector pSANG14-3F
[7]. This vector fuses the antibody to alkaline phosphatase to
drive dimerization and facilitate production of antibody prod-
uct and subsequent detection of binding. It also introduces a
hexahistidine tag for purification and a tri-FLAG tag for
detection of binding via secondary anti-FLAG antibodies
(Sigma). Sub-cloning of selected populations prior to screen-
ing also increased success rate by reducing the proportion of
growth-advantaged clones with truncated inserts in the
screened population. Selected antibody gene populations
were amplified by PCR from the glycerol stocks of the second
round of selection using M13 LeadSeq (5'-AAATTATTAT-
TCGCAATTCCTTTGGTTGTTCCT-3') and NotMycSeq (5'-
GGCCCCATTCAGATCCTCTTCTGAGATGAG-3') primers.
The amplified DNA was run on a 1% agarose gel; insert
excised and purified using a QiaQuick PCR purification kit
(Qiagen, Crawley, UK). Two micrograms of the purified PCR
products were digested with NcoI and NotI restriction
enzymes (New England Biolabs) and electrophoresed in a 1%
agarose/TBE gel. The DNA was purified from the gel slice
using the QiaQuick gel purification kit (Qiagen) and then
ligated into the NcoI/NotI digested pSANG14-3F expression
vector using T4 DNA ligase (New England Biolabs). After
purification of the DNA from the ligation reaction, the ligated
product was electroporated into electrocompetent BL21
(DE3) cells (Novagen). Ninety-four clones per target were
picked, grown and stored at -80°C.
Primary screening of selected populations
The primary and secondary screening ELISAs were per-
formed essentially as described previously [7]. All primary
screening ELISAs were performed on scFv released from bac-
terial pellets, following overnight induction, using Bug Buster
lysis buffer (Novagen). For the primary screening ELISA, we
initially performed the screening assay in a 96-well format
using direct detection of scFv binding via the alkaline phos-
phatase fusion protein and addition of pNPP substrate
(Sigma). For each target, one 96-well flat bottomed Maxisorp
polystyrene plate (Nunc, Roskilde, DK) was coated with the
specific antigen and one ELISA plate with the appropriate
control antigen (for example, MBP, Fc, Trx). The scFvs were
assayed as single points on each plate and any scFv with a spe-
cific antigen signal ≥3-fold higher than the control was scored
as a positive. Later assays were performed in 384-well ELISA
plates using time resolved fluorescence, which involves using
europium labeled secondary detection (Perkin Elmer, Bea-
consfield, UK) to mirror the secondary screening assay. Here,
for each target, one 384-well flat bottomed black polystyrene
plate (Nunc Maxisorp) was coated with both the specific anti-
gen and with the appropriate control antigen. ScFv binding
was detected using an anti-FLAG secondary antibody (Sigma)
conjugated to europium (Perkin Elmer). Again, an antibody
clone was deemed to be antigen specific in the primary
screening ELISA where the mean of the two replicate scores
on the target antigen was at least three-fold greater than the
mean of the two replicate scores for the control protein.Genome Biology 2007, 8:R254
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The secondary screening ELISA was used to identify cross-
reactive antibodies. ScFv was produced by overnight growth
in 1 ml of auto-induction media [34] in a 96-well deep well
microtitre plate (Costar, Lowell, MA, USA). Periplasmic
extracts was prepared by centrifugation at 3,000 g for 10 min-
utes followed by resuspension in 40 μl TES buffer (50 mM
TrisHCl, pH 8.0, 1 mM EDTA, 20% (w/v) sucrose, 2 μl/ml
protease inhibitor cocktail set VII (CalBioChem, Nottingham,
UK)). After 5-10 minutes 60 μl of a one-fifth dilution of TES
supplemented with 2.5 mM MgCl, 2 μl/ml protease inhibitor
cocktail set VII, and 25 U/ml Benzonase (VWR, Lutterworth,
UK) were added. Recombinant antibody fused to alkaline
phosphatase (scFv-AP) was mixed with phosphate-buffered
saline (PBS)/1% milk protein then transferred to pre-blocked
384-well assay plates for development of the ELISA. For con-
venience, the scFv-AP-antigen binding step was performed
overnight at 4°C. Six 384-well ELISA plates were required to
screen each plate of clones. There were two antigens per 384-
well plate coated in duplicate for the panel of 12 antigens. The
antigen panel comprised the specific antigen, a fusion partner
control, keyhole limpet hemocyanin, thyroglobulin,
myoglobin, cytochrome c, human IgG, laminin, fibronectin,
α-glycerol phosphate dehydrogenase (Sigma) and total pro-
tein lysates from zebra fish (Danio rerio) and yeast
(Schizosaccharomyces pombe). Plates were washed and
bound scFv-AP detected with an anti-FLAG secondary anti-
body conjugated to biotin (Sigma) followed by a streptavidin-
europium conjugate (Perkin Elmer), which was detected
using time resolved fluorescence.
Sequence analysis
Each plate of 94 scFv clones, corresponding to a single target
antigen, was sequenced using a single forward primer,
pSANG Fwd (5'-TATGAAATACCTGCTGCCGACC-3').
Sequences were analyzed using Blaze 2, software from Cam-
bridge Antibody Technology (Cambridge, UK). Following
alignment, duplicate clones were identified and removed. The
remaining scFv clones were then aligned according to the
sequence of the heavy chain CDR3 region, which is the most
variable segment. Up to 22 clones per target were chosen
based on both their signal-to-noise ranking from the primary
screening ELISA (highest to lowest) and on the diversity of
their HCDR3 amino acid sequences. Selected clones were
'cherry picked' for further sequence and specificity analysis,
with each derivative plate containing four sets of scFv specific
to four different target antigens. The selected scFv clones
were sequenced in depth using six sequencing primers, three
forward primers (VF1: 5'-GGGGAATTGTGAGCGGA-3'; VF2:
5'-GATCGAGATCTCGATCCCGCGA-3'; Hlink: 5'-ACCGCCA-
GAGCCACCTCCGCC-3') and three reverse primers (Llink: 5'-
GGCGGAGGTGGCTCTGGCGGT-3'; VR1: 5'-CGTGCGGCAG-
TAATTTCC-3'; VR2: 5'-TGTAGTAATATCGCCCTGAG-
CAGCC-3'). The reads were assembled using phrap, and a
minimum read depth of 3 was required for all bases before
any consensus call was accepted. The consensus DNA
sequence was subjected to six frame translation and vector
encoded sequences flanking the VH and VL genes identified
(the pelB signal sequence, the scFv linker sequence (Gly4 Ser
Gly4 Ser Gly3 Ala Ser) and the alkaline phosphatase gene). The
closest germline variable region gene was identified and the
various framework and CDRs were identified.
Performance ranking of scFvs using flow cytometry 
calibration beads
Flow cytometry calibration beads with defined numbers of
anti-human IgG receptors (Quantum Simply Cellular anti-
Human IgG bead sets, Bangs Laboratories Inc., Fishers, IN,
USA)) were used to assess antibody performance in flow
cytometry. This allows the generation of beads with defined
amounts of human Fc fused antigens, permitting an assess-
ment of sensitivity limits for selected antibodies. For
example, the set described in Figure 4 used beads with
29,588, 83,460, 204,228, and 618,888 antigen copies per
bead. Beads were incubated with blocking buffer (PBS/0.1%
(w/v) bovine serum albumin (BSA; Sigma)/0.01% (w:v)
NaN3) prior to incubation with an excess of Fc-tagged anti-
gen. Following binding of the antigen, the beads were washed
by centrifugation in blocking buffer (300 × g for 4 minutes),
and blank (uncoated) beads were then added to the pool of
beads. The final bead mixture was dispensed into 96-well
plates. Following a further wash step, as above, 100 μl of scFv
at 2 μg/ml or a suitable control was added to the beads and
allowed to bind for 1 hour on ice. After washing, bound scFv
was detected using anti-FLAG-biotin (Sigma) at 1 μg/ml fol-
lowed by streptavidin-PE (Pharmingen, Oxford, UK) at 0.5
μg/ml. Antigen binding to the beads was confirmed by stain-
ing with an Fc-specific anti-IgG-FITC antibody (Jackson
Immunolaboratories, West Grove, PA, USA). This antibody
did not bind to the beads in the absence of Fc-tagged antigen.
Data were collected using a FC500MPL flow cytometer (Beck-
man Coulter, High Wycombe, UK), WinMDI [41] was used to
create the histogram plots shown in Figure 4, and median flu-
orescence intensities of each of the bead peaks were gener-
ated using the log/log method within the CXP software
(Coulter). The limit of sensitivity for each scFv clone was
determined using the QuickCal v2.3 software (Bangs
Laboratories).
Flow cytometry with ES cells
46C mouse embryonic stem cells were grown in LIF supple-
mented medium in feeder-free adherent culture as described
[42]. This cell line is known to express Jagged-1 [15,42]. Cells
were removed from adherent culture using trypsin EDTA and
stained in 96 U-well plates in 100 μl at 3 × 105/well with all
procedures being performed on ice. ScFv were applied for 1
hour at 1 μg/ml diluted in PBS supplemented with 1% BSA
and 0.01% sodium azide. Following washing, anti-FLAG-
biotin (Sigma; clone M2) was applied at 1 μg/ml diluted in
PBS supplemented with 0.1% BSA and 0.01% sodium azide.
After an hour's incubation, the cells were washed and 100 μl
of streptavidin-phycoerythrin conjugate (Becton Dickinson,Genome Biology 2007, 8:R254
http://genomebiology.com/2007/8/11/R254 Genome Biology 2007,     Volume 8, Issue 11, Article R254       Schofield et al. R254.17Oxford, UK) was applied at 0.5 μg/ml for 30-60 minutes.
After washing, the cells were resuspended in PBS/0.1% BSA/
sodium azide and staining was visualized using a FC500-MPL
flow cytometer. Analysis was performed using WinMDI with
dead cells gated out as determined by forward versus side
scatter profiles. No staining was evident in the absence of
scFv or in the presence of an irrelevant scFv. Histogram plots
showing levels of staining with streptavidin-phycoerythrin
for control and test are shown.
Immunohistochemistry
Frozen tissue arrays of normal adult human tissue and devel-
opmental and adult murine tissue were prepared by Covance
Ltd (Yorkshire, UK) as previously described by Kononen et al.
[43]. These encompassed one slide type of 28 different
human adult tissues or a second slide type of 23 different
adult murine cores, with murine adult sagittal brain and
E14.5 embryo sections added. In each array, two tissue cores
were included from each donor sample and two donors were
used to represent each tissue type. Sections of the microar-
rays were fixed by immersion in acetone at ambient tempera-
ture for 15 minutes, blocked for endogenous alkaline
phosphatase activity (DAKO, Ely, UK) and non-specific pro-
tein interaction. Alkaline phosphatase-fused scFv antibodies
were incubated for 1 hour in blocking solution then an alka-
line phosphatase-labeled anti FLAG tag antibody (Sigma) was
applied for 30 minutes to amplify the quantity of label for
enzyme detection using NBT/BCIP substrate (DAKO), which
was also applied for 30 minutes. Although binding can be
detected directly via the alkaline phosphatase fusion partner,
we have found improved sensitivity using a secondary alka-
line phosphatase labeled antibody [7]. The arrays were coun-
terstained with nuclear fast red (Vector Labs, Peterborough,
UK), dehydrated in alcohol, cleared in xylene and mounted in
Eukitt resinous mountant (ProSciTech, Poway, CA, USA)).
In situ hybridization
E14.5 mouse embryos (C57BL/6JTyrC-Brd) were fixed in
10% neutral-buffered formalin for 48 hours and embedded in
paraffin wax. Eight micrometer sections on super frost +
slides were hybridized with a 1,170 bp digoxygenin-labeled
antisense RNA probe to the mouse Jag1 gene
(ENSMUSG00000027276) generated from a DNA template.
The template was synthesized by RT-PCR with gene specific
primers (Jag1_1_f: CTAGGCCTGGAGCTTCCACATCTGC;
Jag1_1_r: TAATACGACTCACTATAGGGAGCAGTCCCGGTG
GTGAACCTGGAT).
Transcription was performed using an Ambion Maxi-Script
kit with the addition of digoxygenin UTP (Roche, London,
UK). Sixty nanograms of probe were used for hybridization at
65°C for 6 hours, using a Ventana (Illkirch, France) Discovery
platform with BlueMap and RiboMap kits, according to man-
ufacturer's guidelines. The final stringency of washing was 3
× 0.1 SSC at 85°C. Sections were counterstained with Nuclear
Fast Red
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